Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Healthcare Services Industry Analysis

UpdatedSep 08, 2025
DataAggregated Company Financials
Companies157
  • 7D1.1%
  • 3M-0.08%
  • 1Y-26.3%
  • YTD-11.6%

Over the last 7 days, the Healthcare Services industry has risen 1.1%, driven by gains from UnitedHealth Group of 1.8%. In the past year, the industry is down 26%. Looking forward, earnings are forecast to grow by 13% annually.

Industry Valuation and Performance

Has the U.S. Healthcare Services Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 08 Sep 2025US$868.7bUS$2.1tUS$49.3b21.6x17.6x0.4x
Wed, 06 Aug 2025US$744.2bUS$2.1tUS$49.6b20.3x15x0.4x
Fri, 04 Jul 2025US$859.9bUS$2.1tUS$52.7b22.2x16.3x0.4x
Sun, 01 Jun 2025US$870.4bUS$2.1tUS$52.5b21.2x16.6x0.4x
Tue, 29 Apr 2025US$922.3bUS$1.7tUS$49.6b24.1x18.6x0.5x
Thu, 27 Mar 2025US$1.0tUS$1.7tUS$41.5b24x24.6x0.6x
Sat, 22 Feb 2025US$970.5bUS$1.7tUS$40.9b24.3x23.8x0.6x
Mon, 20 Jan 2025US$1.0tUS$2.0tUS$42.3b23x24.6x0.5x
Wed, 18 Dec 2024US$1.0tUS$2.0tUS$41.4b21.9x24.4x0.5x
Fri, 15 Nov 2024US$1.2tUS$2.0tUS$41.4b24.4x28.2x0.6x
Sun, 13 Oct 2024US$1.2tUS$1.9tUS$43.4b24.7x27.8x0.6x
Tue, 10 Sep 2024US$1.2tUS$1.9tUS$43.3b27x27.9x0.6x
Thu, 08 Aug 2024US$1.2tUS$1.9tUS$43.2b25.5x27.1x0.6x
Sat, 06 Jul 2024US$1.1tUS$1.9tUS$43.4b24.1x24.8x0.6x
Mon, 03 Jun 2024US$1.1tUS$1.9tUS$43.3b27x25.3x0.6x
Wed, 01 May 2024US$1.1tUS$1.9tUS$42.7b26x25.6x0.6x
Fri, 29 Mar 2024US$1.1tUS$1.8tUS$49.6b24.1x22.9x0.6x
Sun, 25 Feb 2024US$1.2tUS$1.8tUS$50.1b24x23.1x0.6x
Tue, 23 Jan 2024US$1.1tUS$1.8tUS$50.8b24x22.3x0.6x
Thu, 21 Dec 2023US$1.1tUS$1.8tUS$51.2b22.2x22.4x0.6x
Sat, 18 Nov 2023US$1.1tUS$1.8tUS$51.2b22.1x22.3x0.6x
Mon, 16 Oct 2023US$1.2tUS$1.8tUS$47.4b22.8x24.2x0.7x
Wed, 13 Sep 2023US$1.1tUS$1.8tUS$46.8b21.7x23.2x0.6x
Fri, 11 Aug 2023US$1.1tUS$1.8tUS$46.8b22.2x24.2x0.6x
Sun, 09 Jul 2023US$1.1tUS$1.7tUS$46.1b23.1x23.2x0.6x
Tue, 06 Jun 2023US$1.1tUS$1.7tUS$45.7b22.5x24.4x0.7x
Thu, 04 May 2023US$1.1tUS$1.7tUS$46.0b22.5x23.8x0.6x
Sat, 01 Apr 2023US$1.0tUS$1.4tUS$44.4b21.9x23.5x0.7x
Mon, 27 Feb 2023US$1.1tUS$1.4tUS$44.0b22.3x25x0.8x
Wed, 25 Jan 2023US$1.1tUS$1.4tUS$45.0b20.9x25x0.8x
Fri, 23 Dec 2022US$1.2tUS$1.4tUS$44.4b21.7x26.6x0.8x
Sun, 20 Nov 2022US$1.2tUS$1.4tUS$44.4b20.8x26.6x0.8x
Tue, 18 Oct 2022US$1.1tUS$1.4tUS$46.1b18.9x24.6x0.8x
Thu, 15 Sep 2022US$1.2tUS$1.4tUS$46.1b18.5x25.3x0.8x
Price to Earnings Ratio

25.3x


Total Market Cap: US$1.2tTotal Earnings: US$46.1bTotal Revenue: US$1.4tTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Healthcare Services Industry Price to Earnings3Y Average 23.8x202320242025
Current Industry PE
  • Investors are pessimistic on the American Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 17.6x which is lower than its 3-year average PE of 23.8x.
  • The industry is trading close to its 3-year average PS ratio of 0.63x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 2.3% per year over the last three years.
  • Revenues for these companies have grown 15% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market0.46%
Healthcare0.82%
Healthcare Services1.08%
Healthcare Facilities3.15%
Healthcare Services0.99%
Managed Healthcare0.95%
Healthcare Distributors0.24%
Industry PE
  • Investors are most optimistic about the Healthcare Distributors industry even though it's trading below its 3-year average PE ratio of 37.7x.
    • Analysts are expecting annual earnings growth of 13.8%, which is higher than its past year's earnings growth of 6.3% per year.
  • Investors are most pessimistic about the Managed Healthcare industry, which is trading below its 3-year average of 22.5x.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 20% over the next 5 years.
  • This is better than its past earnings growth rate of 6.5% per year.
  • In contrast, the Managed Healthcare industry is expected to see its earnings grow by 7.8% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
UNH UnitedHealth GroupUS$315.391.8%
+US$5.0b		-46.9%PE13.4x
HCA HCA HealthcareUS$420.774.2%
+US$3.9b		9.3%PE16.5x
HIMS Hims & Hers HealthUS$48.4114.3%
+US$1.4b		246.5%PE56.5x
CI Cigna GroupUS$305.311.5%
+US$1.2b		-14.6%PE16.2x
THC Tenet HealthcareUS$196.186.4%
+US$1.0b		28.0%PE11.7x

Latest News

ASTH
US$29.70
Astrana Health
7D
-7.1%
1Y
-37.3%
UNH
US$315.39
UnitedHealth Group
7D
1.8%
1Y
-46.9%
HCA
US$420.77
HCA Healthcare
7D
4.2%
1Y
9.3%

Expanding Healthcare Services And Capital Allocation Will Yield Value

Analysts raised their price target for HCA Healthcare slightly to $398.57, citing sustained margin strength and operational resilience despite sector policy concerns, with HCA expected to outperform peers due to its scale and proactive mitigation efforts. Analyst Commentary HCA’s Q2 results showed margin outperformance despite softer volumes, but analysts caution about future margin pressures from compensation ratios and potential policy-related increases in bad debt.
MOH
US$174.65
Molina Healthcare
7D
-3.4%
1Y
-46.0%

Winning RFPs And Medicaid Adjustments Will Secure Future Healthcare Success

Analysts have revised their outlook on Molina Healthcare to a more cautious stance due to higher-than-expected cost trends, expense pressures, and regulatory uncertainties impacting earnings visibility and risk pool quality, resulting in a lowered consensus price target from $201.36 to $196.71. Analyst Commentary Bearish analysts cite higher-than-expected cost trends and broad-based expense pressures within managed care and exchange businesses, leading to lower earnings visibility for Molina Healthcare.
HUM
US$307.92
Humana
7D
1.4%
1Y
-10.4%

AI, In-Home Visits, Medicaid And CenterWell Will Improve Care Delivery

Humana’s modestly higher fair value reflects improving investor sentiment, positive management commentary on future plan positioning, raised earnings guidance, and incremental legislative benefits, offset by some caution around interest rates and policy uncertainty, resulting in the consensus analyst price target rising slightly from $293.05 to $294.86. Analyst Commentary Improved investor sentiment and sector group valuations suggest estimates may have bottomed, with upcoming catalysts including government budget deals, Medicare Advantage and ACA pricing, and star ratings for future plans.
THC
US$196.18
Tenet Healthcare
7D
6.4%
1Y
28.0%
GH
US$60.13
Guardant Health
7D
-10.8%
1Y
153.0%
CVS
US$73.78
CVS Health
7D
0.9%
1Y
30.7%

Digital Health Transformation And Integrated Care Will Expand Reach

Despite ongoing external risks and policy uncertainty, analysts remain constructive on CVS Health, citing strong recent execution, conservative guidance with potential for upside, and compelling valuation, resulting in the consensus price target holding steady at $81.57. Analyst Commentary Bullish analysts cite strong recent execution and early signs that fixes in the healthcare benefits segment are proving effective, supporting above-consensus earnings growth projections.
ELV
US$313.64
Elevance Health
7D
-1.6%
1Y
-42.3%

AI-Enabled Analytics And Value-Based Care Will Ensure Future Stability

Following disappointing Q2 results and a significant EPS guidance cut for 2025, analysts remain cautious on Elevance Health due to earnings uncertainty and operational risks—despite some offsetting segmental strengths and longer-term positives—resulting in an unchanged consensus price target of $368.44. Analyst Commentary Bearish analysts lowered price targets following Elevance Health’s Q2 report, citing a larger-than-expected EPS guidance cut for 2025, lingering questions about the true earnings floor, and persistent volatility in cost trends.
UHS
US$190.12
Universal Health Services
7D
4.7%
1Y
-16.1%

Outpatient Behavioral Health Expansion And Digital Health Will Redefine Healthcare

Analysts maintained their price target for Universal Health Services at $218.31 as improving but still disappointing behavioral health volumes and ongoing start-up losses were offset by the benefits from Tennessee Medicaid expansion, resulting in no change to fair value. Analyst Commentary Behavioral health volumes are showing improvement but remain below internal expectations.
NEO
US$7.98
NeoGenomics
7D
-9.1%
1Y
-47.3%

Advanced Oncology Diagnostics And NGS Capabilities Will Create Future Opportunities

The higher analyst price target for NeoGenomics reflects an expansion in its future P/E multiple despite stable revenue growth forecasts, resulting in a revised fair value of $9.78. What's in the News U.S. District Court invalidated certain Natera patents asserted against NeoGenomics’ RaDaR v1.1 test, but the decision does not affect the '035 patent that previously led to a permanent injunction on RaDaR v1.0. NeoGenomics launched NEO PanTracer LBx, a blood-based comprehensive genomic profiling (CGP) test targeting the expanding liquid biopsy market and enhancing its pan-solid tumor CGP portfolio.
CI
US$305.31
Cigna Group
7D
1.5%
1Y
-14.6%
NAKA
US$4.08
Kindly MD
7D
-25.0%
1Y
209.1%
HIMS
US$48.41
Hims & Hers Health
7D
14.3%
1Y
246.5%
ALHC
US$15.86
Alignment Healthcare
7D
-3.1%
1Y
68.5%
CRVL
US$85.48
CorVel
7D
-4.0%
1Y
-14.6%